{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:30:40Z","timestamp":1740162640963,"version":"3.37.3"},"reference-count":22,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the prevalence and predictors of oral to intravenous antibiotic switch among adult emergency department (ED) patients with acute bacterial skin and skin structure infections (ABSSSIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Multicentre, pilot cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Three urban EDs in Dublin, Ireland.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Consecutive ED patients aged &gt;16 years old with ABSSSIs between March 2015 and September 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Oral flucloxacillin 500\u2009mg\u20131 g four times a day (alternative in penicillin allergy).<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>The primary outcome was to determine the prevalence and predictors of oral to intravenous antibiotic switch. Secondary outcomes were to determine the prevalence and predictors of receiving an extended course of oral antibiotic treatment and measurement of interobserver reliability for clinical predictors at enrolment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 159 patients were enrolled of which eight were lost to follow-up and five were excluded. The majority of patients were male (65.1%) and &lt;50 years of age (58.2%). Oral to intravenous antibiotic switch occurred in 13 patients (8.9%; 95% CI 4.8% to 14.7%). Increased lesion size (OR 1.74; 95%\u2009CI 1.09 to 2.79), white cell count (OR 1.32; 95%\u2009CI 1.05 to 1.67), athlete\u2019s foot (OR 8.00; 95%\u2009CI 2.31 to 27.71) and fungal nail infections (OR 7.25; 95%\u2009CI 1.99 to 26.35) were associated with oral to intravenous antibiotic switch. 24.8% (95% CI 18.1% to 33.0%) of patients received an extended course of oral antibiotic treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prevalence of oral to intravenous antibiotic switch in this pilot study is 8.9% (95% CI 4.8% to 14.7%). We identify the predictors of oral to intravenous switch worthy of future investigation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\" xlink:href=\"NCT02230813\">NCT02230813<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2019-034057","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:10:16Z","timestamp":1598857816000},"page":"e034057","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and predictors of oral to intravenous antibiotic switch among adult emergency department patients with acute bacterial skin and skin structure infections: a pilot, prospective cohort study"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02230813","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4179-2748","authenticated-orcid":false,"given":"Michael","family":"Quirke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarlath","family":"Varley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-0046","authenticated-orcid":false,"given":"Fiona","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Moughty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"McKeever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-5783","authenticated-orcid":false,"given":"Tom","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-2388","authenticated-orcid":false,"given":"Abel","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,30]]},"reference":[{"key":"2020083100100790000_10.8.e034057.1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg466"},{"key":"2020083100100790000_10.8.e034057.2","doi-asserted-by":"publisher","DOI":"10.1086\/644617"},{"key":"2020083100100790000_10.8.e034057.3","doi-asserted-by":"publisher","DOI":"10.1053\/ajem.2001.28330"},{"key":"2020083100100790000_10.8.e034057.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.06.028"},{"key":"2020083100100790000_10.8.e034057.5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit122"},{"key":"2020083100100790000_10.8.e034057.6","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research . Guidance for industry. acute bacterial skin and skin structure infections: developing drugs for treatment, 2013. Available: http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071185.pdf"},{"key":"2020083100100790000_10.8.e034057.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"2020083100100790000_10.8.e034057.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2007.12.004"},{"key":"2020083100100790000_10.8.e034057.9","doi-asserted-by":"publisher","DOI":"10.3201\/eid1509.081228"},{"key":"2020083100100790000_10.8.e034057.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw431"},{"key":"2020083100100790000_10.8.e034057.11","unstructured":"Clinical Resource Efficiency Support Team . Crest guidelines on the management of cellulitis in adults. Northern Ireland: DHSS, 2005: 1\u201331."},{"key":"2020083100100790000_10.8.e034057.12","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/846453"},{"key":"2020083100100790000_10.8.e034057.13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr554"},{"key":"2020083100100790000_10.8.e034057.14","doi-asserted-by":"publisher","DOI":"10.1017\/S1481803500014342"},{"key":"2020083100100790000_10.8.e034057.15","doi-asserted-by":"publisher","DOI":"10.1111\/acem.12371"},{"key":"2020083100100790000_10.8.e034057.16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/acem.13492","article-title":"Predictors of oral antibiotic treatment failure for Nonpurulent skin and soft tissue infections in the emergency department","volume":"26","author":"Yadav","year":"2019","journal-title":"Acad Emerg Med"},{"key":"2020083100100790000_10.8.e034057.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008150"},{"key":"2020083100100790000_10.8.e034057.18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15186"},{"key":"2020083100100790000_10.8.e034057.19","unstructured":"Mortimer PS , Cefai C , Keeley V . Consensus document on the management of cellulitis in lymphoedema. British Lymphology Society and Lymphoedema Support Network 2005."},{"key":"2020083100100790000_10.8.e034057.20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF03169130","article-title":"Using HIPE data as a research and planning tool: limitations and opportunities: a response","volume":"174","author":"Wiley","year":"2005","journal-title":"Ir J Med Sci"},{"key":"2020083100100790000_10.8.e034057.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10275.x"},{"key":"2020083100100790000_10.8.e034057.22","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.ajem.2016.05.064","article-title":"Failure of antibiotics in cellulitis trials: a systematic review and meta-analysis","volume":"34","author":"Obaitan","year":"2016","journal-title":"Am J Emerg Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-034057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T14:49:52Z","timestamp":1696603792000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-034057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,30]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2019-034057"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-034057","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}